PA-SYNERGIS-SOFTWARE
9.3.2022 15:24:09 CET | Business Wire | Press release
Synergis Software, a global leader in engineering document management and workflow solutions, today announced a rebrand and new website in synchrony with major investments in product development and customer success. These initiatives will fast track the company’s delivery of superior products and services to their global customer base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220309005289/en/
“We see so much opportunity to have a positive impact on the customers we serve, which is why we’re making major investments in the company," states Scott Lamond, vice president of marketing at Synergis Software. "We want our brand to align with our mission of transforming the way our customers work— providing greater clarity, control, alignment, and harmony—so they can accelerate engineering projects, streamline operations, reduce risk, and lower costs." Watch the rebrand video .
The Adept platform is used by 120,000 users worldwide, including Dow Chemical, Con Edison, Amazon, Merck, and General Mills, and is managing over $1B in digital assets.
“Adept manages billions of dollars of digital assets containing priceless Dow intellectual property, with thousands of users across several dozen global sites," says Teresa Yang, Product Manager, Document Management, Dow Chemical.
Synergis is committed to accelerating the company’s growth and elevating the value delivered to customers with significant investments in their products.
“We’re tripling the size of our software development organization. By the end of 2022, our team will have grown by 218% in just two years,” explains Todd Cummings, vice president of research and development at Synergis. “The added positions include developers, QA staff, product managers, DevOps, SCRUM Masters, and User Experience professionals. Key leaderships roles are in place to help us refine the processes, tools, and methods we use to develop and deliver more value, faster.”
Synergis is investing substantially in the Adept platform, including the upcoming release of a new, integrated visualization solution for 2D and 3D engineering designs and other document types, along with major new feature enhancements and support for new versions of mainstream CAD systems. A new Cloud version of Adept is underway for customers who want to lower their IT costs and simplify deployment and upgrades.
“We’ll continue to build on Synergis Software’s legacy of extraordinary, love-based service and treating customers like family," adds Lamond. Toward that end, Synergis is expanding its customer success team, developing an online “Adept Academy”, and launching three new services options, including:
- Ongoing Technical Consulting - Customers can work one-on-one with a dedicated Adept technical consultant on a regular basis to improve their Adept environment, streamline processes, remove roadblocks, and increase the value of Adept to their organization. Synergis experts will provide strategic and technical guidance on nearly any type of project to help customers reach their goals.
- Remote Adept Administration - Customers can outsource the day-to-day application management and administration of Adept to our experienced technical staff to keep their resources focused on what’s most important to their business. Our managed services will help keep our customer’s Adept environment optimized and lower operating costs.
- Adept Server Hosting - Customers can outsource the hosting of their entire Adept Server environment to free up IT resources, lower operating costs, and improve security.
Synergis Software’s focus and investments in service and support will help maintain their strong leadership position in the market, as validated in the rankings on the G2 software review site.
“We couldn’t have arrived at this moment without 30 years of thoughtful, collaborative, and visionary support from our customer community and the individuals who have shaped us,” added Lamond. “We’re grateful for their influence as we build our future together.”
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects enterprise applications so critical data and business processes can flow seamlessly across the entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, the company's commitment to its customers is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded. For more information, visit SynergisSoftware.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005289/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom